Journal
KIDNEY INTERNATIONAL
Volume 92, Issue 1, Pages 47-66Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2016.12.037
Keywords
chronic kidney disease; magnetic resonance imaging; nephrotoxicity
Categories
Funding
- National Institutes of Health [NS053468, CA137488-15S1]
- National Cancer Institute [HHSN261200800001E]
- Veterans Administration Merit Review Grant
- Walter S. and Lucienne Driskill Foundation
- [R01 HL127153 IND 129441]
- [2R01AR054458]
- [R01 HD081123A]
- [R21CA176519]
- [R21AR066302]
- [R21CA190196]
Ask authors/readers for more resources
Contrast-enhanced magnetic resonance imaging is a commonly used diagnostic tool. Compared with standard gadolinium-based contrast agents, ferumoxytol (Feraheme, AMAG Pharmaceuticals, Waltham, MA), used as an alternative contrast medium, is feasible in patients with impaired renal function. Other attractive imaging features of i.v. ferumoxytol include a prolonged blood pool phase and delayed intracellular uptake. With its unique pharmacologic, metabolic, and imaging properties, ferumoxytol may play a crucial role in future magnetic resonance imaging of the central nervous system, various organs outside the central nervous system, and the cardiovascular system. Preclinical and clinical studies have demonstrated the overall safety and effectiveness of this novel contrast agent, with rarely occurring anaphylactoid reactions. The purpose of this review is to describe the general and organ-specific properties of ferumoxytol, as well as the advantages and potential pitfalls associated with its use in magnetic resonance imaging. To more fully demonstrate the applications of ferumoxytol throughout the body, an imaging atlas was created and is available online as supplementary material.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available